Vigil Neuroscience Inc (VIGL) has provided an announcement.
Vigil Neuroscience, Inc. has announced an update on its IGNITE Phase 2 clinical trial, opting to preserve data for a comprehensive 12-month analysis, foregoing an interim analysis. This move is aligned with the company’s biomarker strategy and aims to expedite the potential accelerated approval pathway for its drug iluzanebart. Final results, covering all patient data at two dosage levels, are expected in the first half of 2025. However, the company cautions that factors like clinical trial delays could affect outcomes, as detailed in their SEC filings.
Find detailed analytics on VIGL stock on TipRanks’ Stock Analysis page.
